Beamtree Holdings Ltd · ASX:BMT
Beamtree — H1 2026 Earnings Presentation
17 slides from Beamtree's earnings presentation, Feb 19, 2026
Slide 1: 1H FY26 Results
1H FY26 Results February 2026 Authorised for release by the Board of Directors
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, February 2026. This presentation may contain statements that are, or may be deemed to be, forward looking stat
Slide 3: Agenda
Agenda Overview 1H FY26 financial highlights AI competitive moat Progress against strategy Pipeline 1H FY26 financial performance Outlook Copyright © Beamtree Holdings Limited – All Rights Reserved 2
Slide 4: 1H FY26 Financial Highlights
1H FY26 Financial Highlights
Slide 5: 1H FY26 Financial Highlights
1H FY26 Financial Highlights Positive 10 % 10 % Break Even Operating $2.9M PcP * PcP Operating Profit Cashflow Annual Recurring Operating Operating Cash Recurring Revenue Profit Cash Flow Revenue (ARR ) Strong liquidity with $ 28 .0M $ 13.5M $0.1M $0. 4 M $4.3M undrawn Debt Facility * PcP refers to
Slide 6: AI Competitive Moat
AI Competitive Moat Deep customer relationships Extensive domain expertise • Trust • Operational and clinical hospital • ROI track record data going back decades • High bar for accuracy • Standards and degrees of complexity which differ by geography • Evolve • Autonomous Coding • Autonomous Data Ent
Slide 7: Our Markets and Products
Our Markets and Products P roduct Co - development United Kingdom Canada • 68m population ACS • 39m population Evolve Saudia Arabia 3 Strong Partners • 38m population KSA Australia • 27m population UK New Zealand • 5m population Global 6 +25 +1,200+ Continents Countries Locations Copyright © Beamtre
Slide 8: Progress against Strategy
Progress against Strategy • Measurable benefits delivered to our customers Improved clinical decision - making and quality (6 - 8x ROI) Coding accuracy (30% reduction in rework costs) Reimbursement outcomes (up to 24x ROI) • Next generation data platform for the UK NHS (Evolve): Our next - generatio
Slide 9: $24m late-stage opportunities in pipeline
$24m late - stage opportunities in pipeline Coding Products & Services Abbott Global, Direct Sales, ADE Coding comprises Evolve & Knowledge Networks Ainsoff $84m 76% $61m International represents 66% $24m 01 engaged in contracting process ANZ represents 34% engaged in 02 contracting process Total Pi
Slide 10: 1H FY26 Financial Performance
1H FY26 Financial Performance
Slide 11: Revenue by Product Segment and Geography ($'M)
Revenue by Product Segment an d Geography ($ ’M) Revenue by Product Segment Revenue by Geography ANZ INTL Non-Recurring Non-Recurring Knowledge Networks Clinical Decision Support Coding & Data Quality Assurance Diagnostic 14.2 14.5 14.2 14.5 +2% +2% 1.0 1.0 1.9 1.9 Total 6.0 Total 5.6 Revenue Revenu
Slide 12: Profit and Loss ($'M)
Profit and Loss ($’M) 1H FY25 1H FY26 Growth on PcP Group Recurring Revenue Recurring Revenue 12.3 13.5 10% +10% Diagnostic 3.7 4.0 8% Coding & data quality assurance 2.8 3.4 21% Clinical decision support 0.2 0.1 (50%) 5.6 6.0 8% Operating Expenses Knowledge networks Non - Recurring Revenue 1.9 1.0
Slide 13: Cash and Liquidity
Cash and Liquidity 1H FY25 1H FY26 Variance Cash flows from operating activities Receipts from customers (inclusive of GST) 15.1 16.8 Positive Operating C ash F low Payments to suppliers and employees (inclusive of GST) (15.2) (16.3) Supported by effective working Interest received 0.0 0.1 capital m
Slide 14: Simplifying ARR for Scale ($M)
Simplifying ARR for Scale ($M) ARR - Restarted ARR - Previously Disclosed Expected churn of $0.8M as the business continues to simplify for scale 29.2 (0.9) Lost ARR Enterprise contract timing and extended procurement cycles, expected to convert in H2 28.3 28.0 Positioned to accelerate in H2 off cle
Slide 15: FY26 Outlook
Beamtree FY26 Outlook
Slide 16: FY26 Outlook
FY26 Outlook Strategy and Team Financial Strategic Review All systems go! Continue to Targeting accelerated Board initiated strategic execute the strategy, and double digit ARR growth for review to examine accelerate revenue growth FY26 and committed to the operational priorities and business being
Slide 17: Thank you
Thank you 16